Pellagra, serotonin and 5-HIAA

In patients with pellagra, levels of serotonin in the serum and of 5-hydroxyindolecetic acid in the urine were consistently higher than in control subjects.     

How Can We Identify the Best Implantation Site for an ECG Event Recorder?

ZELLERHOFF, C., et al. : How Can We Identify the Best Implantation Site for an ECG Event Recorder? The aim of this study was to show how to find the preferable implantation site for an ECG event recorder (ECG‐ER). We compared the quality of bipolar ECG recordings (4‐cm electrode distance, vertical position) in 65 patients at the following sites: left and right subclavicular, left and right anterior axillary line (4th‐5th interspace), left and right of the sternum (4th‐5th interspace), heart apex, and subxyphoidal. The results were compared to the standard ECG lead II. In 30 patients, an additional comparison between vertical and horizontal ECG registrations was done using the same sites. ECG signals in five patients were compared positioning the electrodes towards the skin with turning them towards the muscle during ECG‐ER implantation. The best ECG quality (defined as highest QRS amplitude, best visible P wave and/or pacemaker spike, best measurable QRS duration, and QT interval) and best agreement with the standard lead II was found in 68% on the left of the sternum, significantly less often (P < 0.001 ) on the right of the sternum (14.1%), left subclavicular (6.9%), apical (5.5%) and subxyphoidal (4.2%). A significantly higher QRS amplitude was measured and the P wave was more often visible in the vertical electrode position than in the horizontal position. In all five ECG‐ER patients, there was a good agreement between the bipolar surface ECG at the implantation site and ECG‐ER stored signals. A significant noise signal occurred in all five patients when the ECG‐ER was implanted with electrodes towards the muscle. A P wave was visible in only three of those patients, but there was an insignificantly higher QRS amplitude than in ECG‐ERs implanted with electrodes towards the skin. From these results, it can be concluded that the best implantation site for an ECG‐ER is right or left of the sternum, positioning the electrodes vertically and towards the skin.     

Holter Recordings with Continuous Marker Annotations: A New Tool in Pacemaker Diagnostics

Pacemakers provide marker annotations to facilitate the interpretation of pacemaker electrocardiograms (ECGs) and can be used in cases of suspected pacemaker malfunction or to understand pacemaker behavior. Due to the need for a programmer, only short-term evaluations are possible. We evaluated a prototype Telemetry Data Logger (TDL) designed to continuously transfer markers from the pacemaker to a conventional Holter recorder. A miniaturized telemetry receiving coil was attached to patient's skin above the pacemaker, which was programmed to transmit markers continuously. The TDL, which receives and converts markers into eight positive and eight negative deflections, ranging from -2.5 to +2.5 mV in amplitude, was connected to one channel of a conventional Holter recorder (Tracker 2). We performed 20 Holters in 13 patients who had implanted VDDB or DDDR devices from the same manufacturer and evaluated three versions of software. Marker transmission was possible in all patients, producing Holter ECGs with complete marker annotations. Artifacts occurred < 4 % of the time. A 50-ms rectangular pulse was optimal for marker interpretation. The device, which was easy to use and well accepted by the patients, assisted in the diagnosis of inappropriate pacemaker programming, even when the surface ECG seemed to show regular pacemaker function. In the presence of low quality surface ECGs, marker annotations allowed the assessment of pacemaker function. The capability to annotate the onset of special algorithms, like tachycardia termination algorithms or mode switching, facilitates interpretation of pacemaker behavior, enabling a reliable assessment of the appropriateness of such algorithms. Conclusion: The TDL effectively enables pacemaker markers to be inscribed onto a conventional Holter recording, facilitating the interpretation of pacemaker ECGs and the diagnosis of inappropriate pacemaker programming even when not discernible from the surface ECG alone.     

Pain Sensation during Intradermal Injections of Three Different Botulinum Toxin Preparations in Different Doses and Dilutions

BACKGROUND: Pain sensation associated with injections of botulinum neurotoxin (BoNT) is commonly reported. To date differences in pain sensation between the commercially available products containing BoNT have not been quantified. OBJECTIVES: The pain sensations during injection of Dysport, Botox, Neurobloc, and pure saline (control) were compared. In addition, the nociceptive effect of different volumes used for the dilution of the same BoNT dose was investigated. METHODS: In a prospective, double-blind, controlled trial, 10 healthy subjects were injected intradermally with Dysport (12 U), Botox (3 and 4 U), Neurobloc (150 and 300 U) reconstituted in 0.9% saline, and pure saline. Pain sensation was quantified during injections. RESULTS: Neurobloc injections caused significantly more injection pain than Botox, Dysport, and saline. No significant differences between Dysport, Botox, and saline were found, although there was a trend toward less pain with pure saline injections. Higher pain levels with higher volumes could not be demonstrated significantly. CONCLUSION: Our data demonstrate that BoNT type B injections are associated with substantial pain. There is a considerable difference between the commercially available BoNT type B compared to the two BoNT type A preparations. Therefore, considering mitigation of injection pain seems necessary when using BoNT type B.     

A Simple Method for Preoperative Assessment of the Best Fitting Electrode Length in Single Lead VDD Pacing

For single lead VDD pacing, electrodes with various distances between the lead tip and the floating atrial dipole (AV distance) are available. Using different AV distances allows positioning of the atrial dipole in the mid- to high right atrium, regardless of the size of the right heart. In this position, reliable atrial sensing and rejection of ventricular far-field potentials can be expected. A simple test for the preoperative assessment of the best fitting AV distance in the individual patient was tested. We studied 24 consecutive patients prior to implantation of AVDD pacemaker. With the patient in supine position, a test electrode with an AV distance of 13 cm was taped onto the thorax. Under fluoroscopic control, it was moved until its course and projection onto the heart was equal to that of a ventricular lead. If fluoroscopy then showed a projection of the atrial dipole onto the mid- to high right atrium, a lead with a similar AV distance of 13 or 13.5 cm was used for implantation. If the atrial dipole projected itself too high or too low, a shorter or longer lead had to be implanted. The maximum time for the test was 2 minutes, and the maximum fluoroscopy time was 15 seconds. According to the test, a lead with an AV distance of 13 or 13.5 cm was implanted in 18 of 24 patients, and a lead with an AV distance of 15.5 or 16 cm was implanted in 6 of 24 patients. The atrial dipole could easily be positioned in the mid- to high right atrium in all patients, demonstrating a correct preoperative assessment of the best fitting AV distance. Intraoperatively, a P wave amplitude of 3.5 ± 3.0 mV was measured. The described test allows a fast and reliable assessment of the best fitting electrode length in single lead VDD pacing.     

Reduction of Pacing Output Coupling Capacitance for Sensing the Evoked Response

SPERZEL, J., et al. : Reduction of Pacing Output Coupling Capacitance for Sensing the Evoked Response. Sensing of the intracardiac evoked response (ER) after a pacing stimulus has been used in implantable pacemakers for automatic verification of capture. Reliable detection of ER is hampered by large residual afterpotentials associated with pacing stimuli. This led to the development of various technological solutions, like the use of triphasic pacing pulses and low polarizing electrode systems. This study investigated the effect of reducing the coupling capacitance (CC) in the pacemaker output circuitry on the magnitude of afterpotential, and the ability to automate detection of ventricular evoked response. A CC of 2.2 μF and four different blanking and recharge time settings were clinically tested to evaluate its impact on sensing of the ventricular ER and pacing threshold. Using an automatic step‐down threshold algorithm, 54 consecutive patients, aged 70 ± 10 years with acutely (n = 27 ) or chronically (n = 27 ) implanted ventricular pacing leads were enrolled for measurement testing. Routine measurements, using a standard pacing system analyzer (PSA), were (mean ± SD ) impedance 569 ± 155 Ω, R wave amplitude baseline to peak 9.8 ± 3.7 mV and threshold 0.9 ± 0.7 V at 0.4‐ms pulse width. This new capture verification scheme, based on a CC of 2.2 μF and recharge/blanking timing setting of 10/12 ms, was successful in 52 patients which is equivalent to a success rate of 96%. In a subgroup of 26 patients implanted with bipolar ventricular leads (10 chronic, 16 acute), data were collected in unipolar (UP) and bipolar (BP) pace/sense configurations. Also, ER signals were recorded with two different band‐pass filters: a wider band (WB) of 6–250 Hz and a conventional narrow band (NB) of 20–100Hz. WB sensing from UP lead configuration yielded statistically significant larger signal to artifact ratios (SAR) than the other settings (P < 0.01). A dedicated unipolar ER sensing configuration using a small output capacitor and a wider band‐pass filter enables adequate automatic capture verification, without any restrictions on pacing lead models or pacing/sensing configurations.